Amicus Therapeutics Newsroom

Amicus Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow JonesDec 13 07:09 ET

Amicus Therapeutics Analyst Ratings

BenzingaDec 13 06:59 ET

Morgan Stanley Downgrades Amicus Therapeutics(FOLD.US) to Hold Rating, Cuts Target Price to $12

Moomoo NewsDec 12 20:32 ET

J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $17

Moomoo NewsNov 12 12:32 ET

Amicus Therapeutics Price Target Raised to $17.00/Share From $16.00 by JP Morgan

Dow JonesNov 12 10:23 ET

Amicus Therapeutics Analyst Ratings

BenzingaNov 12 10:14 ET

J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

Moomoo NewsNov 8 08:32 ET

A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $21

Moomoo NewsNov 8 08:15 ET

Amicus Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating

TipRanksNov 8 02:31 ET

Amicus Therapeutics Is Maintained at Buy by Guggenheim

Dow JonesNov 7 14:34 ET

Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Raises Price Target to $21

BenzingaNov 7 10:44 ET

A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $20

Moomoo NewsNov 7 08:10 ET

Amicus Therapeutics Analyst Ratings

BenzingaNov 7 04:49 ET

Amicus Therapeutics: Strong Financial Performance and Growth Prospects Justify Buy Rating

TipRanksNov 6 14:07 ET

TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsOct 23 07:31 ET

BofA Securities Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $15

Moomoo NewsOct 18 08:32 ET

Amicus Therapeutics Analyst Ratings

BenzingaOct 17 12:59 ET

Amicus Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow JonesOct 11 12:32 ET

Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $18

Moomoo NewsOct 11 08:31 ET

Amicus Therapeutics Analyst Ratings

BenzingaSep 20 12:16 ET